Diabetes Research and Clinical Practice
Volume 77, Issue 3 , Pages 389-398 , September 2007

Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: A comparison of responders and non-responders

  • Masahiko Igarashi

      Affiliations

    • Department of Laboratory Medicine, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 23 628 5316; fax: +81 23 628 5318.
    • ,
  • Yumi Jimbu

      Affiliations

    • Third Department of Internal Medicine, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
    • ,
  • Minako Kimura

      Affiliations

    • Third Department of Internal Medicine, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
    • ,
  • Akihiko Hirata

      Affiliations

    • Department of Laboratory Medicine, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
    • ,
  • Hiroshi Yamaguchi

      Affiliations

    • Third Department of Internal Medicine, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan
    • ,
  • Makoto Tominaga

      Affiliations

    • Department of Laboratory Medicine, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan

Received 18 May 2006 ,Revised 2 October 2006 ,Accepted 26 December 2006.

References 

  1. Kannel WB, McGee DL. Diabetes and cardiovascular disease, the Framingham study. JAMA. 1979;241:2035–2038
  2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart diseases and in non-diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998;339:229–234
  3. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. JAMA. 1998;280:140–146
  4. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1998;37:1595–1606
  5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000;321:405–412
  6. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes study. Diabetes Care. 1999;22:920–924
  7. DECODE Study Group . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Ann. Intern. Med. 2001;161:397–405
  8. Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care. 1992;15:1075–1078
  9. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193–203
  10. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitecomb RW. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J. Clin. Endocrinol. Metab. 1998;83:3169–3176
  11. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care. 2000;23:1605–1611
  12. Kipnes MS, Krosnick A, Rendell MS, Eagan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. 2001;111:10–17
  13. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 1998;83:1818–1820
  14. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Morioka S, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am. J. Cardiol. 2002;89:318–322
  15. Choi D, Jang Y, Kim SK, Lim SK, Choi SH, Lee HC, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27:2654–2660
  16. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. PROactive investigators, secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  17. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolinedione is a high-affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem. 1995;270:12953–12956
  18. Devaraj S, Vega G, Lange R, Grundy SM, Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am. J. Med. 1998;104:445–450
  19. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: result from the Framingham Heart Study. Atherosclerosis. 2001;154:229–236
  20. Chiarugi L, Prisco D, Antonucci E, Capanni M, Fedi S, Liotta AA, et al. Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis. 2001;154:129–135
  21. Duriez P, Dallongeville J, Fruchart JC. Lipoprotein(a) as a marker for coronary heart disease. Br. J. Clin. Pract. Suppl. 1996;77A:54–61
  22. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti A–I immunoaffinity mixed gels. Clin. Chim. Acta. 1993;223:53–71
  23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  24. Kuehnle HF. New therapeutic agents for the treatment of NIDDM. Exp. Clin. Endocrinol. Diabetes. 1996;104:93–101
  25. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493–2499
  26. Araki T, Emoto M, Yokoyama H, Motoyama K, Morioka T, Tahara H, et al. Insulin resistance index as a predictor for pioglitazone treatment in type 2 diabetes. Osaka City Med. J. 2005;51:19–25
  27. Blüher M, Lübben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care. 2003;26:825–831
  28. Gavin LA, Barth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr. Pract. 2000;6:305–310
  29. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 1998;338:867–872
  30. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J. 1998;316:823–828
  31. Collins R, Armitage J, Parish S, Sleight P, Peto R Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–767
  32. Colhoun HM, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  33. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am. J. Epidemiol. 2001;153:490–499
  34. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029–1036
  35. Couch SC, Isasi CR, Karmally W, Blaner WS, Starc TJ, Kaluski D, et al. Predictors of postprandial triacylglycerol response in children: the Columbia University Biomarkers Study. Am. J. Clin. Nutr. 2000;72:1119–1127
  36. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin. Ther. 2004;26:744–754
  37. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–1554
  38. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762–2770
  39. Tomono S, Kawazu S, Kato N, Ono T, Ishii C, Ito Y, et al. Uptake of remnant-like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J. Atheroscler. Thromb. 1994;1:98–102
  40. Ai M, Tanaka A, Ogita K, Sekine M, Numano F, Reaven GM. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J. Am. Coll. Cardiol. 2001;38:1628–1632
  41. Igarashi M, Hirata A, Yamauchi T, Yamaguchi H, Tsuchiya H, Ohnuma H, et al. Clinical utility and approach to estimate postprandial hypertriglycemia by a newly designed oral fat-loading test. J. Atheroscler. Thromb. 2003;10:314–320
  42. Ginsberg HN. Insulin resistance and cardiovascular disease. J. Clin. Invest. 2000;106:453–458
  43. Pakala R, Kuchulakanti P, Rha SW, Cheneau E, Baffour R, Waksman R. Peroxisome proliferator-activated receptor γ: its role in metabolic syndrome. Cardiovasc. Radiat. Med. 2004;5:97–103
  44. Majali KA, Cooper MB, Staels B, Luc G, Taskinen MR, Betteridge DJ. The effect of sensitization to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia. 2006;49:527–537
  45. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation. 2000;102:1082–1085
  46. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999;100:1154–1160
  47. Matsumoto K, Miyake S, Yano M, Tominaga Y. Increase of lipoprotein (a) with tro-glitazone. Lancet. 1997;350:1748–1749
  48. Ovalle F, Bell DS. Troglitazone's effect on lipoprotein (a) levels. Diabetes Care. 1999;22:859–860
  49. Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. Relationship between apoprotein (a) phenotype and increase of lipoprotein (a) by troglitazone. Metabolism. 1999;48:1–2
  50. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur. J. Clin. Invest. 2006;36:91–97

PII: S0168-8227(07)00043-5

doi: 10.1016/j.diabres.2006.12.022

Diabetes Research and Clinical Practice
Volume 77, Issue 3 , Pages 389-398 , September 2007

Article Tools

* Image Usage & Resolution